Xiaofei J. Jiao

Wuhan, 430030, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Treatment implications of T cell DNA damage in anti-tumor immunity.

Treatment implications of T cell DNA damage in anti-tumor immunity.

Journal: Cancer biology & medicine

Published: May 21, 2026

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy.

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: March 25, 2026

Treatment Advances in Gynecologic Cancers: Insights From Recent Clinical Trials.

Treatment Advances in Gynecologic Cancers: Insights From Recent Clinical Trials.

Journal: Cancer innovation

Published: January 21, 2026

Deep learning prediction model based on multi-modal transvaginal ultrasound scan images for endometrial cancer.

Deep learning prediction model based on multi-modal transvaginal ultrasound scan images for endometrial cancer.

Journal: Cancer imaging : the official publication of the International Cancer Imaging Society

Published: November 11, 2025

ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer.

ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: October 20, 2025

Sequential treatment with PARPi and WEE1i enhances antitumor immune responses in preclinical models of ovarian cancer.

Sequential treatment with PARPi and WEE1i enhances antitumor immune responses in preclinical models of ovarian cancer.

Journal: Science translational medicine

Published: August 13, 2025

ATR-mediated phosphorylation of RIPK1 inhibits DNA damage-induced necroptosis.

ATR-mediated phosphorylation of RIPK1 inhibits DNA damage-induced necroptosis.

Journal: Biochemical pharmacology

Published: May 31, 2025

Withdrawal notice to "ATR-mediated phosphorylation of RIPK1 inhibits DNA damage-induced necroptosis" [Biochemical Pharmacology 237 (2025) 116949].

Withdrawal notice to "ATR-mediated phosphorylation of RIPK1 inhibits DNA damage-induced necroptosis" [Biochemical Pharmacology 237 (2025) 116949].

Journal: Biochemical pharmacology

Published: May 27, 2025

Mitigating T cell DNA damage during PARP inhibitor treatment enhances antitumor efficacy.

Mitigating T cell DNA damage during PARP inhibitor treatment enhances antitumor efficacy.

Journal: Science translational medicine

Published: May 07, 2025

Sensorimotor simulation and distributed processing of biological motion: Insights from healthy and paraplegic adults.

Sensorimotor simulation and distributed processing of biological motion: Insights from healthy and paraplegic adults.

Journal: Psychonomic bulletin & review

Published: March 15, 2025

Withdrawal notice to: ATR-mediated phosphorylation of RIPK1 inhibits DNA damage-induced necroptosis.

Withdrawal notice to: ATR-mediated phosphorylation of RIPK1 inhibits DNA damage-induced necroptosis.

Journal: Biochemical pharmacology

Published: January 27, 2025

IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial.

IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial.

Journal: Med (New York, N.Y.)

Published: October 22, 2024

Showing 1-12 of 33

Last Updated: 09/26/2026